664 completed, 100 terminated, 90 unknown, 75 recruiting. 1049 Phase 3, 145 Phase 2.
Follow Connective Tissue Diseases: new trials by email Literature Review of Connective Tissue Diseases trials Research Report on Connective Tissue Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT Trametinib - HCM, Noonan Syndrome and Other Rasopathy | Phase 3 | Not yet recruiting | Carelon Research | 25 | 2027-08-01 | 2026-09-14 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP) garetosmab - Fibrodysplasia Ossificans Progressiva, FOP | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 18 | 2027-02-02 | 2026-11-12 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| A Pilot Multicentric Open Study Assessing the Efficacy and Safety of NEMOlizumab in Patients ≥ 12yo With Dystrophic Epidermolysis Bullosa Neolizumab - Dystrophic Epidermolysis Bullosa | Phase 2 / Phase 3 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 15 | 2026-12-31 | 2026-11-09 |
| A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further. ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | AbbVie | 580 | 2026-12-11 | 2026-11-12 |
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) Tralesinidase alfa (TA) - MPS IIIB | Phase 3 | Not yet recruiting | Spruce Biosciences | 14 | 2026-12-01 | 2026-09-21 |
| Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus Afimetoran, Placebo - Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2 / Phase 3 | Recruiting | Beeline Medicines Corporation | 390 | 2026-11-03 | 2026-11-10 |
| DEPART Study at Yale Radiation Therapy - Dupuytren's Contracture | Phase 3 | Not yet recruiting | Yale University | 158 | 2026-11-01 | 2026-10-13 |
| Naproxen Versus Placebo as Adjunct Treatment of Cellulitis enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious | Phase 3 | Not yet recruiting | Ottawa Hospital Research Institute | 884 | 2026-11-01 | 2026-10-20 |
| A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] Enpatoran - Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | Phase 3 | Recruiting | EMD Serono Research & Development Institute, Inc. | 404 | 2026-10-22 | 2026-11-10 |
| the Effect of Ginkgo Biloba on Rheumatoid Arthritis Patients Ginkgo Biloba Extract (120 mg ) manufuctured by EMA PHARM - Rheumatoid Arthritis (RA), Manegmentof Rheumatoid Arthritis | Phase 2 / Phase 3 | Not yet recruiting | Ain Shams University | 50 | 2026-10-15 | 2026-10-06 |
| The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution - Ehlers-Danlos Syndrome, Low Back Pain | Phase 3 | Withdrawn | Tulane University | 2026-10-05 | 2026-10-08 | |
| A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) obinutuzumab (RO5072759) - Lupus Nephritis | Phase 3 | Not yet recruiting | Zhao Minghui | 70 | 2026-09-10 | 2026-08-26 |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Nicorandil in Atherosclerosis Risk in Patients With Rheumatoid Arthritis Nicorandil 10 MG Oral scored Tablet, DMARD maintenance - Rheumatoid Arthritis (RA, Atherosclerosis | Phase 3 | Not yet recruiting | Tanta University | 46 | 2026-09-01 | 2026-09-11 |
| A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus Anifrolumab - Lupus Erythematosus, Systemic | Phase 3 | Recruiting | AstraZeneca | 417 | 2026-08-31 | 2026-10-22 |
| Perioperative Haemostasis, Procedure-Related Pain After Physiological or Pharmacological Modifications of Local Anaesthesia Around the Eyes Sodium Bicarbonate (NaHCO3), Warmed lignocaine, Hyaluronidase Injection - Dermatochalasis of Upper Eyelid, Blepharoplasty | Phase 3 | Not yet recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 80 | 2026-08-01 | 2026-08-03 |
| Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon Botulinum toxin A via microneedle, Control (Normal saline) - Systemic Sclerosis (SSc), Raynaud Disease Secondary to Scleroderma | Phase 3 | Not yet recruiting | Khon Kaen University | 72 | 2026-08-01 | 2026-08-17 |
Showing 20 of 1049. Sign in to see all of them.
Arthritis, Rheumatoid (451) · Lupus Erythematosus, Systemic (119) · Arthritis, Juvenile (79) · Arthritis (57) · Lupus Nephritis (52) · Scleroderma, Systemic (50) · Scleroderma, Diffuse (43) · Cellulitis (37) · Autoimmune Diseases (36) · Dermatomyositis (30) · Osteoarthritis (28) · Sjogren's Syndrome (26) · Polymyalgia Rheumatica (20) · Rheumatic Diseases (20)
Skin and Connective Tissue Diseases (1048) · Immune System Diseases (702) · Autoimmune Diseases (680) · Musculoskeletal Diseases (665) · Rheumatic Diseases (571) · Joint Diseases (559) · Arthritis (517) · Skin Diseases (157) · Pathological Conditions, Signs and Symptoms (143) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (113) · Pathologic Processes (108) · Genetic Diseases, Inborn (91) · Urogenital Diseases (77) · Muscular Diseases (73)
Methotrexate (115) · tocilizumab (94) · Adalimumab (51) · Rituximab (46) · Abatacept (37) · Etanercept (35) · Certolizumab Pegol (31) · Infliximab (29) · Mycophenolic Acid (23) · Cyclophosphamide (20) · baricitinib (19) · tofacitinib (19) · Prednisone (18) · belimumab (17) · golimumab (16)
Hoffmann-La Roche (81) · Bristol-Myers Squibb (32) · Novartis Pharmaceuticals (30) · Amgen (29) · Pfizer (27) · Eli Lilly and Company (22) · UCB Pharma (20) · Abbott (18) · GlaxoSmithKline (17) · AstraZeneca (16) · Genentech, Inc. (15) · AbbVie (13) · Janssen Research & Development, LLC (13) · Sanofi (13) · Assistance Publique - Hôpitaux de Paris (12)
United States (465) · Germany (271) · Spain (235) · France (233) · Poland (220) · Canada (215) · United Kingdom (205) · Italy (197) · Mexico (193) · Argentina (175) · Brazil (167) · Japan (162) · South Korea (162) · Australia (156) · Hungary (155)
Takahiro Kakehi (8)
PMID 27338778, PMID 33687069, PMID 29244149, PMID 30649524, PMID 33263165, PMID 36526796, PMID 36600185, PMID 36601090, PMID 36931693, PMID 28143815, PMID 32816215, PMID 33127856, PMID 34870800, PMID 37453736, PMID 25047021, PMID 33874971, PMID 30177460, PMID 34041702, PMID 34706874, PMID 35577477, PMID 36715850, PMID 36754548, PMID 36814062, PMID 37308218, PMID 37945286, PMID 37982966, PMID 38958913, PMID 39192350, PMID 40875187, PMID 22491018, PMID 26275429, PMID 29463520, PMID 29949132, PMID 30219772, PMID 31610021, PMID 33059710, PMID 33115760, PMID 34921355, PMID 36125701, PMID 37925660, PMID 41448717, PMID 24429164, PMID 24498318, PMID 27889300, PMID 29246162, PMID 30054164, PMID 30058112, PMID 32414425, PMID 33057725, PMID 34519964
2023 (36), 2009 (17), 2015 (17), 2016 (11), 2008 (10), 2019 (10), 2014 (9), 2017 (9), 2018 (9), 2025 (7), 2005 (6), 2004 (4), U01AR042540 (2), N01AR022265 (1), P60AR047784 (1)